Molecular Cancer Therapeutics

Molecular Cancer Therapeutics Molecular Dynamics Molecular Dynamics Simulation... 

Bialkowska A.B. Crisp M. Bannister T. He Y. Chowdhury S. Schurer S. Chase P. Spicer T. Madoux F. Tian C. Hodder P. Zaharevitz D. Yang, V.W. Identification of small-molecule inhibitors of the colorectal cancer oncogene Kriippel-like factor 5 expression by ultrahigh-throughput screening. Molecular Cancer Therapeutics, 2011, 10, 2043-2051. 

H. L. (2002) Transforming growth factor beta mimetics discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Molecular Cancer Therapeutics,... 

Sankaranarayanapdlai, M., Tong, W.P., Maxwell, D.S., Pal, A., Pang, J., Bornmann, W.G., Gelovani, J.G. and Ronen, S.M. (2006) Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Molecular Cancer Therapeutics, 5, 1325—1334. 

Scott, G.K,Marden, C.,Xu, F., Kirk, L. and Benz, C.C. (2002) Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Molecular Cancer Therapeutics,... 

J. J. (2006) CRA-026440 a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Molecular Cancer Therapeutics, 5, 1693-1701. 

Glaser, KB., Staver, M.J., Waring, J.F., Stender, J., Ulrich, R.G. and Davidsen, S.K. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Molecular Cancer Therapeutics, 2, 151—163. 

Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J. et al. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXDIOI. Molecular Cancer Therapeutics, 2, 721-728. 

Modulation of Histone Acetylation by [4-(Acetylamino)-N-(2-Amino-phenyl) Benzamide] in HCT-8 Colon Carcinoma. Molecular Cancer Therapeutics, 2, 401—4-08. 

Eliseeva, E.D., Valkov, V., Jung, M. and Jung, M.O. (2007) Characterization of novel inhibitors of histone acetyltransferases. Molecular Cancer Therapeutics, 6, 2391-2398. 

Stimson, L., Rowlands, M.G., Newbatt, Y.M., Smith, N.F., Raynaud, F.I., Rogers, P. et al. (2005) Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Molecular Cancer Therapeutics, 4, 1521—1532. 

R. Tides, J. Trent, R. Kurzrock, Tyrosine kinase inhibitors and the da wn of molecular cancer therapeutics, Ann. Rev. Pharmacol. Toxicol. 45 (2005) 357. 

Ireson, C.R., and Kelland, L.R. (2006) Discovery and development of anticancer aptamers. Molecular Cancer Therapeutics 5 2957-2962. 

Teicher BA. Molecular cancer therapeutics Will the promise be fulfilled In Prendergast GC, editor. Molecular cancer therapeutics Strategies for drug discovery and development. Hoboken, NJ John Wiley Sons, Inc. 2004. p. 8-40. 

Tibes R, Trent J, Kurzrock R (2005) Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 45 357-84... 

Allen,J.D., van Loevezijn, A., Lakhai, J.M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J.H., Koomen, G.J. and Schinkel, A.H. (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Molecular Cancer Therapeutics, 1, 417 -25. 

Qin, C., Morrow, D., Stewart, J., Spencer, K., Porter, W., Smith, R., Ill, Phillips, T., Abdelrahim, M., Samudio, I. and Safe, S. (2004) A new class of peroxisome proliferator-activated receptor y (PPARy) agonists that inhibit growth of breast cancer cells l,l-bis(3 -indolyl)-l-(p-substituted phenyljmethanes. Molecular Cancer Therapeutics, 3, 247-259. 

Lee, E. A, Keutmann, M. K, Dowling, M. L., Harris, E., Chan, G., Kao, G. D. (2004). Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Molecular Cancer Therapeutics, 3, 661-669. 

H., Bearss, D.J., Han, H., Mahadevan, D., Hoff, D.D.V., and Hurley, L.H. (2006) Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Molecular Cancer Therapeutics, 5, 1764-1773. 

Rodon J, DeSantos V, Ferry RJ Jr., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway Lessons from the first clinical trials. Molecular Cancer Therapeutics 2008 7 2575—2588. 

Weng, D. E., et al, A phase 1 clinical trial of a ribozyme-based angiogenesis inhibitor targeting. Vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Molecular Cancer Therapeutics, 2005. 4(6) pp. 948-955. 

Takekoshi, T., Ziarek, J. J., Volkman, B. P., Hwang, S. T. (2012). A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. Molecular Cancer Therapeutics, 11(11), 2516-2525. http //dx.doi.org/10.1158/1535-7163.MCT-12-0494. 

Abrams, T.J., Lee, L.B., Murray, L.J., Pryer, N.K., Cherrington, J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in precUnical models of human small cell lung cancer. Molecular Cancer Therapeutics 2(5), 471- 78 (2003)... 

Zhang, Y., Tang, L., and Gonzalez, V. 2003. Selected isothiocyanates rapidly induce growth inhi-hition of cancer cells. Molecular Cancer Therapeutics, 2(10), 1045-1052. 

Sinha, R., Kim, G.J., Nie, S. and Shin, D.M. (2005) Nanotechnology in cancer therapeutics bioconjugated nanoparticles for drug delivery. Molecular Cancer Therapeutics, 5, 1909-17. 

I. Collins, P. Workman, New approaches to molecular cancer therapeutics (Review), Nat. Chem. Biol. 2 (2006) 689-700. 

---